Summary by Moomoo AI
Ardelyx, Inc., a biopharmaceutical company traded on the Nasdaq Global Market under the symbol ARDX, has filed a Form 8-K with the U.S. Securities and Exchange Commission on May 22, 2024. The report announces the resignation of Susan Rodriguez from her position as Chief Commercial Officer of Ardelyx. The decision was mutually agreed upon by both parties. To ensure a smooth transition, Ms. Rodriguez will continue to serve in an advisory capacity to the company until the end of 2024. The company's headquarters are located in Waltham, Massachusetts, and it is incorporated in the state of Delaware. No other material events, financial statements, or exhibits were disclosed in the filing.